YATHARTHNSE7 November 2023

Yatharth Hospital & Trauma Care Services Limited has informed the Exchange about Investor Presentation

Yatharth Hospital & Trauma Care Services Limited

November 7, 2023

The Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (E) Mumbai – 400 051

Dept. of Listing Operations BSE Limited, P J Towers, Dalal Street, Mumbai -400001, India

Symbol: YATHARTH

Scrip Code: 543950

Dear Sir/Ma’am,

Sub:-Investor's presentation- Q2 &FY24 Results.

Please find enclosed Investor's Presentation for Q2 & FY24 Results pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015.

Kindly take the same in your records.

Thanking you,

Your faithfully, For Yatharth Hospital and Trauma Care Services Limited

Ritesh Mishra Company Secretary & Compliance Officer Enclosed: As above

m o c

a t

p s o h h t

r a h t a y

w w w

Q2 & H1 FY24 Earnings Presentation

November 7, 2023

Disclaimer

Certain matters discussed in this Presentation may contain statements regarding the company’s market

opportunity and business prospects that are individually and collectively forward-looking statements. Such

forward-looking statements doesn’t guarantee future performance and are subject to known and unknown

risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but

are not limited to, the performance of the economy,

industry, competition, the company’s ability to

successfully implement its strategy, technological

implementation, changes and advancements, the

company’s market preferences and its exposure to market risks, as well as other risks. The company’s actual

results, levels of activity, performance or achievements could differ materially and adversely from results

expressed in or implied by this presentation. The company assumes no obligation to update any forward-

looking information contained in this presentation. Any forward-looking statements and projections made

by third parties included in this presentation are not adopted by the company and the company is not

responsible for such third-party statements and projections. You are cautioned not to place undue reliance

on these forward-looking statements, which are based on the current view of the management of the

Company on future events.

Q2 & H1 FY24 Performance Highlights

Q2 & H1 FY24 Financial Highlights

Margin 26.6% +40bps YoY

Margin 16.1% +345bps YoY

Rs. 1,713 mn +34% YoY +11% QoQ

Rs. 456 mn +36% YoY +10% QoQ

Rs. 276 mn +70% YoY +45% QoQ

Net Cash Rs. 3,109 mn

Revenue

Rs. 3,258 mn +36% YoY

Rs. 870 mn +47% YoY

Rs. 466 mn +71% YoY

Margin 26.7% +192bps YoY

Margin 14.3% +293bps YoY

RoCE 25%

RoE 19%

EBITDA

PAT

Capital

➢ Yatharth Hospitals turns net debt-free during the quarter ➢ Finance cost reduces by 42% YoY and 50% QoQ to Rs. 29 mn during the quarter. Full Impact of debt reduction on

finance cost to be further visible during Q3

Financial Highlights

Revenue (Rs mn)

EBITDA (Rs mn) & EBITDA%

+34%

9 7 2 , 1

+11%

3 1 7 , 1

5 4 5 , 1

+36%

8 5 2 , 3

0 9 3 , 2

Q2FY23

Q1FY24

Q2FY24

H1FY23

H1FY24

Finance Cost (Rs mn)

5 9

9 8

9 5

0 5

9 2

1000 99 5 99 0 98 5 98 0 975 970 96 5 96 0 95 5 95 0 94 5 94 0 935 930 925 920 915 910 90 5 90 0 89 5 89 0 88 5 88 0 875 870 86 5 86 0 85 5 85 0 84 5 84 0 835 830 825 820 815 810 80 5 80 0 795 790 785 780 775 770 765 760 755 750 745 740 735 730 725 720 715 710 705 700 69 5 69 0 68 5 68 0 675 670 66 5 66 0 65 5 65 0 64 5 64 0 635 630 625 620 615 610 60 5 60 0 59 5 59 0 58 5 58 0 575 570 56 5 56 0 55 5 55 0 54 5 54 0 535 530 525 520 515 510 50 5 50 0 49 5 49 0 48 5 48 0 475 470 46 5 46 0 45 5 45 0 44 5 44 0 435 430 425 420 415 410 40 5 40 0 395 390 385 380 375 370 365 360 355 350 345 340 335 330 325 320 315 310 305 300 295 290 285 280 275 270 265 260 255 250 245 240 235 230 225 220 215 210 205 200 195 190 185 180 175 170 165 160 155 150 145 140 135 130 125 120 115 110 105 100 95 90 85 80 75 70 65 60 55 50 45 40 35 30 25 20 15 10 5 0

26.2%

26.8%

26.6%

5 3 3

4 1 4

6 5 4

Q2FY23

Q1FY24

Q2FY24

27%

26%

25%

24%

23%

22%

21%

20%

19%

18%

17%

16%

15%

14%

13%

12%

11%

10%

27%

26%

23%

22%

21%

20%

19%

18%

17%

16%

15%

14%

13%

12%

11%

10%

16.1%

6 7 2

12.7%

12.3%

2 6 1

0 9 1

PAT (Rs mn) & PAT%

24%

25%

24.8%

26.7%

0 7 8

2 9 5

H1FY23

H1FY24

14.3%

6 6 4

11.4%

2 7 2

27%

26%

25%

24%

23%

22%

21%

20%

19%

18%

17%

16%

15%

14%

13%

12%

11%

10%

27%

26%

25%

24%

23%

22%

21%

20%

19%

18%

17%

16%

15%

14%

13%

12%

11%

10%

Q2FY23

Q1FY24

Q2FY24

H1FY23

H1FY24

Q2FY23

Q1FY24

Q2FY24

H1FY23

H1FY24

Strengthened Balance Sheet

40%

Debt Repayment – 2,450 mn

Equity Base Expansion (Rs mn)

8,065

Rs 6,100 mn IPO Proceeds

22%

11%

27%

Organic Capex – 1,326 mn

Inorganic Expansion – 650 mn

1,830

General Corporate & Issue Exps. – 1,674 mn

Ongoing Capex (Rs mn)

Particulars

Machinery & Equipment purchase at all hospitals

Capex Incurred till Sep 30, 2023

58 mn

Mar-23

Sep-23

Debt Repayment (Rs mn)

2,674

Mar-23

132

Sep-23

Operational Highlights

❑ Occupancy increases to 57% in Q2FY24, vs 45% in Q2FY23 and 50% in Q1FY24; Noida and Greater Noida hospital reported

highest occupancy levels of 96% and 73% respectively during the quarter

❑ Inpatient revenue up by 37% YoY during the quarter, and 40% YoY during the half-year period

❑ ARPOB is Rs. 27,833 in H1 FY24, up by 6% YoY; Noida extension hospital reported highest ARPOB of Rs. 33,181 in H1 FY24

❑ Nephrology & urology and neurosciences grew 40%+, while Gastroenterology, Pulmonology and Oncology grew over 2x on a

YoY basis; Radiation oncology line has arrived at Noida extension, and is expected to start operations in Jan-24, offering full

spectrum of oncology treatment, while robotic surgeries is expected to start operations in the coming quarter

❑ The Income Tax Department conducted a search operation at the Company premises from October 19th to 22nd, 2023 and did

not find any preliminary unaccounted cash or incriminating evidences during the said operation. The company is duly

replying to the queries of the tax authorities and does not foresee any impact on the operating and financial performance of

the company

Operational KPIs

IPD & OPD Revenue (Rs mn)

IPD & OPD Volumes (in ‘000s)

IPD Revenue

OPD Revenue

1,545

186

1,359

1,713

224

1,489

1,279

192

1,087

2,389

352

2,037

3,258

410

2,848

IPD Volume

OPD Volume

188

185

101

166

H1FY23

161

H1FY24

Q2FY23

Q1FY24

Q2FY24

H1FY23

H1FY24

Q2FY23

Q1FY24

Q2FY24

Revenue Mix – H1FY24 (%)

ALOS (days)

29%

36%

Greater Noida

Noida Extension

Noida

Jhansi-Orchha

4.95

4.79

4.63

4.22

4.12

ALOS – Average Length of Stay

30%

Q2FY23

Q1FY24

Q2FY24

H1FY23

H1FY24

Operational KPIs

) n m s R ( e u n e v e R

) s R ( B O P R A

) % ( y c n a p u c c O

1,279

1,545

1,713

497

444

317

559

465

443

613

488

529

949

825

585

1,172

953

971

162

Q2FY23

Q1FY24

Q2FY24

H1FY23

H1FY24

2,389

3,258

6 3 1 , 1 3

8 4 6 4 2

8 6 1 , 6 2

5 6 2 8 1

9 3 4 5 2

6 2 9 3 3

9 9 7 5 2

0 4 1 , 8 2

2 3 2 0 2

4 1 0 8 2

1 8 5 2 3

9 8 5 5 2

1 6 5 , 7 2

6 2 7 7 1

4 6 6 7 2

4 9 3 0 3

5 0 6 4 2

2 0 3 6 2

5 2 2 8 1

1 6 0 6 2

1 8 1 , 3 3

1 9 6 5 2

3 3 8 , 7 2

4 6 8 8 1

0 3 8 7 2

Q2FY23

Q1FY24

Q2FY24

H1FY23

H1FY24

91%

64%

92%

66%

45%

28%

50%

37%

17%

96%

73%

85%

57%

60%

45%

20%

42%

27%

94%

70%

54%

41%

19%

Greater Noida

Noida

Noida Extension

Jhansi-Orchha

Consolidated

Q2FY23

Q1FY24

Q2FY24

H1FY23

H1FY24

Our Specialties

H1 FY24 Mix (%)

Cardiology

10%

Diversified specialty services

2023

31%

10%

6% 5% 5% 4% 3% 9%

Internal

Medicine

33%

Nephrology &

urology, 10%

2022

50%

Oncology, 3%

Gynecology, 4%

Gastroenterology, 4%

Neurosciences

General surgery,

2021

56%

Pediatrics, 4%

Others*, 6%

Pulmonology

Orthopedics &

spine &

rheumatology

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Internal Medicine Cardiology General Surgery Pediatrics Gynecology Others

Neurosciences Nephology & Urology Orthopedics, Spine & Rehumatology Pulmonology Gastroenterology

Clinical Achievements

Profit & Loss Summary

Particulars (Rs Mn)

Q2FY24

Q2FY23

Revenue from Operations

1,713

1,279

Medical Consumables & Pharmacy items

Employee Expenses

Other Expenses

EBITDA

360

284

613

456

231

237

475

335

Change YoY

34%

56%

20%

29%

36%

Q1FY24

1,545

281

268

582

414

Change QoQ

H1FY24

H1FY23

Change YoY

11%

28%

10%

3,258

2,390

641

552

1,195

870

444

433

921

592

36%

44%

27%

30%

47%

EBITDA Margin %

26.6%

26.2%

40 bps

26.8%

(20 bps)

26.7%

24.8%

192 bps

Depreciation and amortisation

Financial Cost

Other Income

Profit Before Tax (PBT)

Tax

Profit After Tax (PAT)

396

120

276

230

162

10%

(42%)

443%

72%

76%

70%

294

103

190

(51%)

375%

35%

17%

45%

138

689

223

466

123

387

115

272

12%

(6%)

254%

78%

94%

71%

PAT Margin %

16.1%

12.7%

345 bps

12.3%

380 bps

14.3%

11.4%

293 bps

Balance Sheet

Particulars (Rs Mn)

Sep-23

Mar-23

Particulars (Rs Mn)

Sep-23

Mar-23

Shareholders Equity

8,065

1,830

Fixed Assets (including Goodwill)

2,925

2,950

Borrowings

Lease Liabilities

Trade Payables

Other financial liabilities

Other liabilities and provisions

105

146

162

169

142

2,638

Right to Use Assets

Financial Assets

Inventories

Total Liabilities

8,542

4,860

Other assets

3,240

535

384

333

Trade Receivables

1,741

1,076

Cash & Bank Balances

Total Assets

8,542

4,860

About The Company

At a Glance Leading super specialty hospital in Delhi-NCR

Among top 10 largest private hospitals of Delhi NCR region in terms of number of beds

One-stop destination for patient needs providing all levels of healthcare services from primary to tertiary

2019 Noida Extension

2013 Noida

2010 Greater Noida

1,405

Hospitals

Center of Excellence

Operational Beds

Rs. 27,833

ARPOB*

4.79 days

ALOS*

2022 Jhansi-Orchha

Revenue

EBITDA

PAT

RoCE

*H1FY24 figures

3 2 Y F

4 2 Y F 1 H

Rs 5,203mn FY21-23 CAGR +51%

Rs 1,338mn Margin 25.7% FY21-23 CAGR +41%

Rs 658mn Margin 12.6% FY21-23 CAGR +90%

26.1%

Rs 3,258mn +36% YoY

Rs 870mn Margin 26.7% +190bps YoY

Rs 466mn Margin 14.3% +290bps YoY

24.5%

Our Journey Growing presence across regions and services

2008

Incorporation of company and commencement of operations

2013

2019

2023

Established our second 250 bedded hospital, in Noida

Commencement of our third hospital, Noida Extension hospital, in May 2019, pursuant to the acquisition of subsidiary AKS in 2016

Listing on NSE & BSE

Established our first hospital in Greater Noida

Expansion of our first hospital, Greater Noida hospital, to 400 beds

Acquisition of 4th hospital - Jhansi Orchha hospital adding 305 beds, pursuant to acquisition of subsidiary, Ramraja

2010

2018

2022

Continued expansion into specialized services - Neurology, Cardiology, Nephrology, Orthopedics and Oncology

Plan to introduce radiation therapy and liver transplant operations

Greater Noida Hospital Overview

Revenue from Operations (Rs mn) 1,994

1,702

811

949

1,172

Provides a wide spectrum of super specialty services in the field of

cardiology, cardiovascular and thoracic surgery, neurology, neurosurgery,

urology, nephrology, oncology, gastroenterology etc.

Strategy to develop this hospital as the Centre of Excellence for Human

Organ Transplant and as a major center for medical tourism

Company has acquired land parcel of 1,885 sq mt adjacent to hospital,

FY21

FY22

FY23

H1FY23

H1FY24

aimed towards expansion of bed capacity to 600 from 400 presently

In-Patient and Out-Patient Volume

116,300

137,937

82,520

69,328

69,269

9,322

15,020

17,255

8,634

8,726

FY21

FY22

FY23

H1FY23

H1FY24

In-Patient Volume

Out-Patient Volume

ARPOB (Rs)

ALOS (days)

9 3 5 6 2

0 3 8 , 7 2

1 2 6 3 2

4 5 7 , 1 2

4.8

4.4

4.0

FY21

FY22

FY23

H1FY24

FY21

FY22

FY23

H1FY24

2010 Incorporated

400 Bed Capacity

112 ICU

70% Occupancy

Note: H1FY24 figures

Noida Hospital Overview

Revenue from Operations (Rs mn) 1,721

Provides services across 30 specialties,

including cardiac sciences,

orthopedics, nephrology, urology, neurosciences, gastroenterology, etc.

1,283

681

825

953

Strategy to improve ALOS and improve the combination of super

specialties, for better ARPOB

FY21

FY22

FY23

H1FY23

H1FY24

In-Patient and Out-Patient Volume

44,671

56,799

72,906

35,858

36,821

7,816

9,316

11,957

6,073

6,248

FY21

FY22

FY23

H1FY23

H1FY24

In-Patient Volume

Out-Patient Volume

ARPOB (Rs)

ALOS (days)

1 9 6 5 2

9 4 9 4 2

6 3 4 , 1 2

7 1 6 , 2 2

6.1

5.8

5.9

4.1

FY21

FY22

FY23

H1FY24

FY21

FY22

FY23

H1FY24

2013 Incorporated

250 Bed Capacity

81 ICU

94% Occupancy

Note: H1FY24 figures

Noida Extension Hospital Overview

Revenue from Operations (Rs mn)

Plan to develop this hospital as a Centre of Excellence for oncology

1,357

1,023

795

treatment and robotic surgeries

971

Plan to start liver transplant operations; recently started bone marrow and

585

kidney transplant operations. Radiation oncology line expected to be

commissioned by Jan-24, offering full spectrum of oncology treatments

FY21

FY22

FY23

H1FY23

H1FY24

In-Patient and Out-Patient Volume

Company is declared as highest bidder for an adjacent land, which will

support future bed capacity expansion

102,278

8,564

49,730

52,893

46,258

4,218

8,457

14,186

6,862

7,646

FY21

FY22

FY23

H1FY23

H1FY24

In-Patient Volume

Out-Patient Volume

ARPOB (Rs)

ALOS (days)

1 8 1 , 3 3

5 7 4 0 3

4 3 5 4 2

0 1 7 , 0 2

9.1

4.9

3.1

3.8

FY21

FY22

FY23

H1FY24

FY21

FY22

FY23

H1FY24

2019 Incorporated

450 Bed Capacity

125 ICU

41% Occupancy

Note: H1FY24 figures

Jhansi – Orchha Hospital Overview

Revenue from Operations (Rs mn)

One of the largest hospital in Jhansi-Orchha-Gwalior region, has

162

infrastructure to operate all the major super specialties

131

FY23

H1FY23

H1FY24

In-Patient and Out-Patient Volume

16,639

7,785

8,548

1,960

462

1,800

FY23

H1FY23

H1FY24

In-Patient Volume

Out-Patient Volume

ARPOB (Rs)

ALOS (days)

4 6 8 8 1

2 9 6 , 7 1

4.8

3.8

FY23

H1FY24

FY23

H1FY24

Acquired in FY22, aimed at further expanding into new geographies and

growing presence in the regional healthcare market

Plan to introduce a fully functional oncology treatment unit in FY2025

2022 Incorporated

305 Bed Capacity

76 ICU

19% Occupancy

Note: H1FY24 figures

Our Specialties Expanding share of high value specialties

30 Specialties and Super specialties including 10 Centers of Excellence (COE)

Our COEs ➢ Centre of Internal Medicine

➢ Centre of Cardiology

➢ Centre of Neurosciences

➢ Centre of General surgery

➢ Centre of Nephrology & Urology

➢ Centre of Pediatrics

➢ Centre of Gastroenterology

➢ Centre of Pulmonology

➢ Centre of Gynecology

➢ Centre of Orthopedics & Spine &

Rheumatology

FY21-23 CAGR

) n m . s R ( e u n e v e R

a n r e t n

13%

66%

77%

72%

82%

65%

79%

108%

131%

209%

53%

Revenue change - FY23 vs FY21

FY2021

FY2023

7 3 6 , 1

9 0 5

2 4 4

e n c d e M

s e c n e c s o r u e N

y g o o d r a C

y r e g r u S

a r e n e G

3 7 4

& y g o o h p e N

y g o o r U

5 9 2

y g o o t a m u h e R

& e n p S

0 3 2

5 6 2

8 5 1

2 4 2

y g o o c e n y G

s c i r t a d e P

y g o o r e t n e o r t s a G

y g o o n o m u P

7 4 1

s r e h t O

s c d e p o h t r

▪ Increase in share of higher value specialties such as Cardiology and

Neurosciences, leading to higher ARPOB

▪ Organ transplant operations started in December 2022 ▪ Radiation oncology lines expected to be commissioned by January 2024, while

robotic surgeries expected to start in the coming quarter

Payer mix Balanced revenue split between payer categories

Self-payers

1,605

1,888

FY22

FY23

Insurers through TPA

1,227

1,381

FY22

FY23

Government Bodies

1,177

1,934

FY22

FY23

885

FY21

669

FY21

733

FY21

Figures in Rs mn

FY2023

Self-payers

and others

36%

Central, state

and local

government

bodies

under

government

scheme

37%

Insurers acting through

third party

administrators

27%

OUR STRENGTHS

Strengths

Among the leading super-specialty hospital in Delhi NCR

Regional advantage

Advanced and high-end medical equipment and technology

Experienced and professional management team

Team of highly qualified medical professionals

Track record of stable operating & financial performance

Leading hospital in Delhi NCR, attracts patients from adjoining states with inadequate healthcare facilities

Delhi NCR region

Jhansi-Orchha- Gwalior

2 of Yatharth’s hospitals are amongst top 10 largest private hospitals in Delhi NCR*

➢ Noida, Greater Noida and Noida extension attract patients from the

NCR region, other nearby states and even internationally

➢ Even with high bed densities, hospitals in the region have shown high occupancy rates indicating potential for further growth and expansion

➢ Opportunity to expand in other tier II cities of Northern India

➢ Diversified mix in terms of specialties, hospitals and customers

allows to maintain a relatively de-risked business proportions

Particulars

Delhi-NCR

Noida

Greater Noida

Noida Extension

Ghaziabad

Jhansi- Orchha- Gwalior

Population - 2021

~70 million

~0.8 million

~0.4 million ~6.5 million

~3.7 million

# Hospital beds

~163,000

~4,300

~2,500

~1,000

~7,200

~7,900

*In terms of number of beds in FY2023

# Source: CRISIL

Regional Advantage

Integrating talent from well-established allied workforce

First mover advantage in building out network across Tier II/III cities

Stronger local connect with people

Promoters being doctors, have better connect with doctors

Advanced and high-end medical equipment and technology

• Hospitals are equipped with machines and devices with sophisticated technology •

Strive to introduce cutting-edge medical technology and state-of-the-art equipment

• Catheterization Laboratory • Computerized Tomography Scan

Diagnostic Equipment

Certifications

(CT Scan)

• Magnetic Resonance Imaging (MRI) • State of the art imaging equipment - Mammography, Advanced EEG, Nerve conduction velocity, advanced surgical equipment etc.

• •

All hospitals are NABH accredited Received NABL certification for Noida Extension hospital, and Greater Noida hospital

• Well-equipped modular and other operation theatres with three stage air filtration and laminar flow • Operating microscopes, image intensifiers, and laparoscopic equipment

Operation Theatres

• Critical care units are equipped

•

with high-end patient monitoring devices, ventilators and dedicated isolation rooms Facilities for haemodialysis, sustained low-efficiency dialysis, endoscopy and bronchoscopy are available 24x7 by the bedside

Critical care Equipment

Team of highly qualified medical professionals

Number of Doctors (Sep’23)

Full Time Employees (Sep’23)

Visiting

Doctors, 164

Specialist

Doctors, 253

Resident

Medical

Doctors, 224

Nursing, 877

398

Paramedical,

Corporate and

Support Staff,

1,823

Resident

Medical

Doctors, 224

Specialist

Doctors, 253

Attrition to ease amidst strategic initiatives

Specialist Doctors

Resident Medical Doctors

❑ Introduced DNB program across 8 specialties in 2 of the hospitals ❑ DNB program to reduce attrition of Resident Medical Doctors ❑ Total 24 resident doctors have joined the DNB program till date

Other Staff

❑ Keep staff abreast with global developments concerning the

health sector

❑ Provide better doctor visibility amongst the potential patients

through marketing and awareness campaigns

34%

43%

Experienced and professional management team

Leadership Promoted by experienced medical professionals, Dr. Ajay Kumar Tyagi and Dr. Kapil Kumar

Management Led by experienced and qualified professional management team

Brand Strong brand equity led by ✓ First mover advantage in regional

territories

✓ One of the best healthcare infra ✓ Personalized connect with patients

Dr. Ajay Kumar Tyagi Chairman & Whole-time Director

Dr. Kapil Kumar Managing Director

Yatharth Tyagi Whole-time Director

Amit Kumar Singh Chief Executive Officer

Deepak Kumar Tyagi President, Strategy and Finance

Pankaj Prabhakar Chief Financial Officer

Track record of stable operating and financial performance

1. Stable operating &

financial performance

2. Continued growth over the past

three fiscals

Growth led by strong operational efficiency: 1.

Streamlining clinical and administrative functions

2. Continually introducing process

innovations

3. Maintaining economies of scale

Optimizing Capex Allocation 1. Reinvesting in increasing bed

capacity and opening new hospitals Incurring lower capital expenditure per operational bed

3. Making optimal use of the available area in our hospitals and working better with equipment suppliers

FY21-23 CAGR Revenue: 51% EBITDA: 41%

4,009

5,203

2,287

n m s R

670

1,108

1,338

) e u n e v e r

f o % ( 3 2 Y F

27%

18%

17%

26%

21%

FY21

FY22

Revenue

FY23

EBITDA

Material and

Employee Cost

EBITDA Margin

Consumables

Yatharth

Peer Average

800 .00

700 .00

600 .00

500 .00

400 .00

300 .00

200 .00

100 .00

0.0 0

n m s R

3.91

3.72

7 3 3

FY21

9 0 4

FY22

4.0 0

3.0 0

2.0 0

1.0 0

0.0 0

3.07

2 3 4

FY23

Gross Capex

Capex per Operational Bed

Growth Strategy

Continue to improve our quality of care and operational efficiencies

Introduce new specialties at existing hospitals

Grow medical tourism segment to attract international patients

Further leverage technology to grow operations

Augment scale through organic and inorganic manner in current markets and expand into adjacent regions

Key Growth Drivers (1/2)

Improving specialty mix towards high value specialties

Introduce new specialties at existing hospitals

Grow medical tourism segment to attract international patients

➢ Increase in share of higher value such as Neurology, Nephrology, Oncology,

specialties Cardiology, Orthopedics resulting in higher ARPOB

and

➢ Further

super- strengthening of specialties by on-boarding new reputable and experienced doctors

➢ Incremental

organ share transplant in Greater Noida & Noida Extension to enhance mix of high value specialties

➢ Noida Extension taking the lead by offering radiation line for oncology treatments

➢ Close proximity to the upcoming Asia’s largest airport at Greater Noida

➢ Kidney Transplant already started at Noida Extension & Greater Noida, and liver transplant to start soon

➢ Focus on orthopedics,

cardiac sciences, gastrointestinal surgery international for and patients

urology

➢ Align marketing strategies to target

medical tourists

➢ Started soft marketing of radiation

line

Key Growth Drivers (2/2)

Targeting Balanced Growth

Leverage technology to grow operations

Improving utilization & Jhansi hospital stabilization

➢ Augment scale through organic and inorganic manner in current markets and expand into adjacent regions

➢ Expand in Tier II cities of Northern

➢ Adopt

the

latest

medical technologies and equipment to improve the quality of care and of success augment surgeries

rates

India

➢ Plan to introduce robotic surgeries

➢ Acquired adjacent land parcels in Greater Noida & Noida extension, to support future growth opportunities

➢ Focus towards increasing ARPOB and better management of ALOS in Noida, Greater Noida & Noida Extension

➢ Jhansi operations began in FY23, with a utilization of 8%. With stabilization of Jhansi hospital, ARPOB & utilization to improve in the coming quarters

Appendix

Board of Directors (1/2)

Dr. Ajay Kumar Tyagi Chairman & Whole-time Director

Dr. Kapil Kumar Managing Director

Yatharth Tyagi Whole-time Director

➢ Over 17 years of experience in medical

➢ Over 17 years of experience in medicine

➢ Associated with the company since 2019

care and hospital management

and healthcare

➢ Associated with the Company since its

incorporation

➢ Previously associated with Medical Health Family Welfare U.P. L.K.O

➢ Holds a degree of bachelor of medicine, bachelor of surgery, and diploma in orthopaedics

➢ Previously associated with Lady Hardinge Medical College, Smt. Sucheta Kriplani Hospital and Noida Orthopedic Hospital

➢ Holds a degree of bachelor of medicine,

bachelor of surgery, and master of surgery in orthopedic surgery. Also completed magister chirurgie in orthopedics

➢ Holds a bachelor’s degree in business and management from Leeds Beckett University, United Kingdom and holds a master of science degree in International Health Management from Imperial College, London

➢ Responsible for overall operations and business development for the company

Board of Directors (2/2)

Promila Bhardwaj Independent Director

Mukesh Sharma Independent Director

Sanjeev Upadhyaya Independent Director

➢ Over 35 years of experience in public

➢ Over 35 years of experience in banking

➢ Over 20 years of experience in

administration

➢ Previously associated with Bank of

community medicines

➢ Joined Indian revenue services in the

Baroda

year 1979, and retired as DGIT (Systems) from Directorate of Income Tax (systems)

➢ Holds a degree of bachelor of arts and master’s of arts in English, master of philosophy in social sciences, and master’s diploma in public administration

➢ Holds a bachelor’s degree in science

agriculture & animal husbandry, master’s degree in business administration and post graduate diploma in labour law, labour welfare and personnel management, also holds a degree of bachelor’s of law

➢ Previously associated with E.S.I. Hospital, Aga Khan Foundation Project, United Nations’ Children’s Fund and other organizations

➢ Holds a bachelor’s degree in medicine and bachelor of surgery, and doctor of medicine in community medicine

Management Team

Amit Kumar Singh Chief Executive Officer

Pankaj Prabhakar Chief Financial Officer

Deepak Kumar Tyagi President, Strategy and Finance

➢ Over 17 years of experience in hospital

management

➢ Over 16 years of experience incorporate finance of several healthcare institutions

➢ Approximately 14 years of experience

incorporate finance

➢ Previously associated with Centre for

➢ Previously associated with Rockland

Sight, Raksha Medicare Private Limited, Veeda Clinical Research Private Limited, Indira Gandhi Eye Hospitals, Radiant Life Care Private Limited

➢ Holds bachelor’s degree in art,

postgraduate diploma in Hospital and Health Management

Hospital, Max Devki Devi Heart & Vascular Institute, Fortis Flt. L.T. Rajan Dhall Hospital, Artemis Medicare Services Private Limited, Max Healthcare Institute Limited and Asian Institute of Medical Sciences

➢ Holds a bachelor’s degree and is an associate member of the Institute of Chartered Accountants of India

➢ Previously associated with Prometric Testing Private Limited and Mind Shapers Technologies Private Limited

➢ Holds a Bachelor’s degree in commerce and completed course of study in French from University of Delhi

➢ Associate member of the Institute of

Company Secretaries of India and the Institute of Chartered Accountants of India

Shareholding Pattern

Shareholding Pattern*

19.18%

5.42%

9.07%

Promoter Group

DIIs

FIIs

Others

* As on September 30, 2023

BSE Ticker

543950

NSE Ticker

YATHARTH

66.33%

Market Capitalization*

Rs. 32,434 mn

No. of shares outstanding

8,58,50,233

Thank You

Yatharth Hospital & Trauma Care Services Ltd

CIN: L85110DL2008PLC174706

www.yatharthhospitals.com

Investor Relations

investor.relations@yatharthhospitals.com

m o c

a t

p s o h h t

r a h t a y

w w w

← All Transcripts YATHARTH Stock Page →

Yatharth Hospital & Trauma Care Services Limited has informed the Exchange about Investor Presentation

Market Movers